The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity.
Fiche publication
Date publication
novembre 2017
Journal
Retrovirology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr RUFF Marc
Tous les auteurs :
Amadori C, van der Velden YU, Bonnard D, Orlov I, van Bel N, Le Rouzic E, Miralles L, Brias J, Chevreuil F, Spehner D, Chasset S, Ledoussal B, Mayr L, Moreau F, García F, Gatell J, Zamborlini A, Emiliani S, Ruff M, Klaholz BP, Moog C, Berkhout B, Plana M, Benarous R
Lien Pubmed
Résumé
HIV-1 Integrase (IN) interacts with the cellular co-factor LEDGF/p75 and tethers the HIV preintegration complex to the host genome enabling integration. Recently a new class of IN inhibitors was described, the IN-LEDGF allosteric inhibitors (INLAIs). Designed to interfere with the IN-LEDGF interaction during integration, the major impact of these inhibitors was surprisingly found on virus maturation, causing a reverse transcription defect in target cells.
Mots clés
Allosteric integrase inhibitor, HIV-1, INLAI, Immunoreactivity, Integrase, LEDGF, LEDGIN
Référence
Retrovirology. 2017 Nov 9;14(1):50